按新冠疫苗接种状态估算献血者中SARS-CoV-2血清流行率及原发性SARS-CoV-2感染发病率——美国,2021年4月至2022年9月
分析美国全国纵向献血者队列数据,估算2021年第二季度68.4%的≥16岁人群具有感染或疫苗接种诱导的SARS-CoV-2抗体,至2022年第三季度升至96.4%,其中混合免疫占47.7%;混合免疫流行率在≥65岁人群中最低(36.9%),在16-29岁人群中最高(59.6%)。
要点
- 2021年第二季度68.4%的≥16岁人群有SARS-CoV-2抗体,其中47.5%仅来自疫苗接种,12.0%仅来自感染,8.9%来自两者。
- 至2022年第三季度96.4%有抗体,其中22.6%仅来自感染,26.1%仅来自疫苗接种,47.7%为混合免疫。
- 混合免疫流行率在≥65岁人群中最低(36.9%),在16-29岁人群中最高(59.6%)。
核心结论
- 老年人中感染诱导免疫和混合免疫流行率低反映公共卫生感染预防措施的成功,同时强调老年人应及时接种推荐的新冠疫苗,包括至少1剂二价疫苗。
研究设计与样本
- 分析美国全国纵向献血者队列数据,估算SARS-CoV-2感染发病率及感染或疫苗接种诱导抗体(或两者)的流行率。
主要发现
- 2021年第二季度(4-6月)≥16岁人群中68.4%有感染或疫苗接种诱导的SARS-CoV-2抗体,包括47.5%仅来自疫苗接种、12.0%仅来自感染、8.9%来自两者。
- 2022年第三季度(7-9月)96.4%有既往感染或疫苗接种的SARS-CoV-2抗体,包括22.6%仅来自感染、26.1%仅来自疫苗接种;47.7%有混合免疫。
- 混合免疫流行率在≥65岁人群中最低(36.9%),在16-29岁人群中最高(59.6%)。
临床怎么用
- 老年人中感染诱导和混合免疫流行率低反映公共卫生感染预防措施的成功,同时强调老年人应及时接种推荐的新冠疫苗,包括至少1剂二价疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Changes in testing behaviors and reporting requirements have hampered the ability to estimate the U.S. SARS-CoV-2 incidence (1). Hybrid immunity (immunity derived from both previous infection and vaccination) has been reported to provide better protection than that from infection or vaccination alone (2). To estimate the incidence of infection and the prevalence of infection- or vaccination-induced antibodies (or both), data from a nationwide, longitudinal cohort of blood donors were analyzed. During the second quarter of 2021 (April-June), an estimated 68.4% of persons aged ≥16 years had infection- or vaccination-induced SARS-CoV-2 antibodies, including 47.5% from vaccination alone, 12.0% from infection alone, and 8.9% from both. By the third quarter of 2022 (July-September), 96.4% had SARS-CoV-2 antibodies from previous infection or vaccination, including 22.6% from infection alone and 26.1% from vaccination alone; 47.7% had hybrid immunity. Prevalence of hybrid immunity was lowest among persons aged ≥65 years (36.9%), the group with the highest risk for severe disease if infected, and was highest among those aged 16-29 years (59.6%). Low prevalence of infection-induced and hybrid immunity among older adults reflects the success of public health infection prevention efforts while also highlighting the importance of older adults staying up to date with recommended COVID-19 vaccination, including at least 1 bivalent dose.*,†.
引用
- Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37262007. doi:10.15585/mmwr.mm7222a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。